Joint Bone Spine最新文献

{"title":"French Societies of Rheumatology and of Physical and Rehabilitation Medicine recommendations for the management of people living with hand osteoarthritis","authors":"Alice Courties ,&nbsp;Camille Daste ,&nbsp;Alexis F. Homs ,&nbsp;Inès Kouki ,&nbsp;Françoise Alliot-Launois ,&nbsp;Lisa Bialé ,&nbsp;Pierre-Emmanuel Cailleaux ,&nbsp;Adeline Cambon ,&nbsp;Roland Chapurlat ,&nbsp;Michel Chammas ,&nbsp;Grégoire Cormier ,&nbsp;Marie-Christine Fabre ,&nbsp;Véronique Gaud-Listrat ,&nbsp;Augustin Latourte ,&nbsp;Antonio Lopez ,&nbsp;Emmanuel Maheu ,&nbsp;Nathalie Nayral ,&nbsp;François Rannou ,&nbsp;Anne-Christine Rat ,&nbsp;Alexandra Rören ,&nbsp;Jérémie Sellam","doi":"10.1016/j.jbspin.2025.106000","DOIUrl":"10.1016/j.jbspin.2025.106000","url":null,"abstract":"<div><h3>Objectives</h3><div>To establish French recommendations for the management of people living with hand osteoarthritis (OA) on behalf of the French Society of Rheumatology (SFR) and of the French Society of Physical and Rehabilitation Medicine (SOFMER).</div></div><div><h3>Methods</h3><div>A systematic review of the literature, including systematic reviews, meta-analyses, and randomized controlled trials on pharmacological and non-pharmacological treatments, was conducted from inception until November 24, 2023. Based on this review and expert consensus, a multidisciplinary group of 25 healthcare professionals—including rheumatologists, physical and rehabilitation medicine physicians, hand surgeons, general practitioner, geriatrician, occupational therapists, physiotherapists, and patients—formulated the recommendations. Each statement was assigned a level of evidence, a grade of recommendation, and a level of agreement based on EULAR standardized procedures for recommendations.</div></div><div><h3>Results</h3><div>The group established four general principles and 11 specific recommendations. The general principles emphasize treatment objectives, individualized management, patient education, and a multimodal approach combining non-pharmacological and pharmacological therapies. Four specific recommendations address non-pharmacological strategies, including exercise, ergonomic advice, assistive devices, orthoses and heat applications. The group advises against the use of electromagnetic waves, laser therapy, acupuncture, or kinesiotaping. Seven specific recommendations cover pharmacological treatments, advocating for topical and oral NSAIDs, acetaminophen, chondroitin sulfate for symptom relief, low-dose oral corticosteroids for inflammatory flares, and intra-articular steroid injections for inflammatory painful interphalangeal OA. Given the current data, the group advises against the use of conventional synthetic or biological disease-modifying anti-rheumatic drugs (DMARDs).</div></div><div><h3>Conclusions</h3><div>These recommendations provide a structured approach for the management of people living with hand OA in France, aligning with national healthcare practices and patient needs.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 2","pages":"Article 106000"},"PeriodicalIF":4.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145440153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Piezo1 at the crossroads: Mediating inflammation and mechanical stress in joint disorders","authors":"Siwen Chen ,&nbsp;Zihao Li ,&nbsp;Jingyu Zhang ,&nbsp;Hui Liu","doi":"10.1016/j.jbspin.2025.105953","DOIUrl":"10.1016/j.jbspin.2025.105953","url":null,"abstract":"<div><div>Piezo1 is a mechanosensitive ion channel, which plays a pivotal role in translating mechanical stress into cellular signaling, thereby influencing inflammatory responses and tissue remodeling in joint disorders. Current evidences showed that Piezo1 functions as a mechanotransducer and amplifier of inflammation across joint disorders including osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), and intervertebral disc degeneration (IVDD). In OA, Piezo1 mediates chondrocyte apoptosis and matrix degradation via calcium influx, NF-κB/MAPK activation, and ferroptosis, forming a feedback loop with IL-1α to exacerbate inflammation. In AS, Piezo1 drives pathological new bone formation through CaMKII signaling, synergizing with TNF-α/IL-17A to perpetuate entheseal inflammation. In IVDD, Piezo1-induced calcium dysregulation triggers mitochondrial dysfunction, NLRP3 inflammasome activation, and YAP/TAZ-mediated extracellular matrix (ECM) degradation, creating a self-amplifying cycle of mechanical stress and inflammation. Targeting Piezo1 emerges as a potential therapeutic strategy, with preclinical studies demonstrating inhibition of Piezo1 alleviates disease progression by disrupting mechanotransduction-inflammation crosstalk. However, challenges remain in achieving tissue-specific modulation. Future research should focus on elucidating Piezo1's context and developing precision therapeutics to restore mechanobiological balance in joint diseases.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 2","pages":"Article 105953"},"PeriodicalIF":4.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teleconsultation for rheumatoid arthritis: A selective therapeutic tool in routine care","authors":"Jérôme Avouac,&nbsp;Olivier Fogel,&nbsp;Anna Molto,&nbsp;Yannick Allanore","doi":"10.1016/j.jbspin.2025.105983","DOIUrl":"10.1016/j.jbspin.2025.105983","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 2","pages":"Article 105983"},"PeriodicalIF":4.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical isthmic spondylolysis.","authors":"Alexandre Meynard, Pascale Vergne-Salle, François Caire","doi":"10.1016/j.jbspin.2026.106047","DOIUrl":"https://doi.org/10.1016/j.jbspin.2026.106047","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"106047"},"PeriodicalIF":4.3,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147345821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Answer to Jing, et al","authors":"Yinglun Zhang ,&nbsp;Zhibin Jin ,&nbsp;Jing Yao ,&nbsp;Dandan Wang ,&nbsp;Yunxian Yu ,&nbsp;Weijing Zhang","doi":"10.1016/j.jbspin.2025.106003","DOIUrl":"10.1016/j.jbspin.2025.106003","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 106003"},"PeriodicalIF":4.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin cancer risk in patients with non-dermatologic immune-mediated inflammatory diseases","authors":"Jean-Guillaume Letarouilly ,&nbsp;Pauline Wils ,&nbsp;Delphine Staumont-Sallé ,&nbsp;Denis Jullien ,&nbsp;Laurent Mortier ,&nbsp;Laurent Peyrin-Biroulet ,&nbsp;Christophe Richez ,&nbsp;Marie Boileau ,&nbsp;René-Marc Flipo","doi":"10.1016/j.jbspin.2025.105972","DOIUrl":"10.1016/j.jbspin.2025.105972","url":null,"abstract":"<div><div>Safety issues related to the risk of cancer associated with immune-mediated inflammatory disease (IMID) treatments have always been a major concern. Skin cancer is the most common type of cancer, especially non-melanoma skin cancer (NMSC), with a steadily increasing incidence. Some guidelines recommend that all patients with IMID should undergo regular skin cancer screening due to a combination of treatment-related and disease-related risk factors. However, systematic skin cancer screening is still controversial because there is no substantial evidence that it reduces skin cancer mortality. Furthermore, dermatologists have insufficient resources to screen all IMID patients and need, therefore, to focus on at-risk patients. Such screening could also lead to overdiagnosis. In this review, we will summarise the data on the risk of skin cancer in patients with non-dermatologic IMID according to treatment. We will also propose an algorithm to help the clinician focus on those patients most needing annual skin screening.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105972"},"PeriodicalIF":4.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyostotic fibrous dysplasia of the thoracic cage","authors":"Xingxin Hu,&nbsp;Yao Kong,&nbsp;Bingkui Li","doi":"10.1016/j.jbspin.2025.105968","DOIUrl":"10.1016/j.jbspin.2025.105968","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105968"},"PeriodicalIF":4.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding difficult-to-treat psoriatic arthritis: Data from the Rheumatic Diseases Portuguese Registry","authors":"Catarina Abreu ,&nbsp;Vanessa Fraga ,&nbsp;Sara Dias Rodrigues ,&nbsp;Laura Gago ,&nbsp;Susana Almeida ,&nbsp;Catarina Dantas Soares ,&nbsp;Maria Pontes Ferreira ,&nbsp;Carlos Marques-Gomes ,&nbsp;Mariana Diz-Lopes ,&nbsp;Miguel Bernardes ,&nbsp;João Menezes ,&nbsp;Carolina Ochôa Matos ,&nbsp;Elsa Vieira-Sousa ,&nbsp;Tiago Beirão ,&nbsp;João Oliveira ,&nbsp;Mariana Luís ,&nbsp;Rodrigo Rei ,&nbsp;Rafaela Nicolau ,&nbsp;Cláudia Pinto Oliveira ,&nbsp;Carolina Vilafanha ,&nbsp;Maria José Santos","doi":"10.1016/j.jbspin.2025.105949","DOIUrl":"10.1016/j.jbspin.2025.105949","url":null,"abstract":"<div><h3>Objectives</h3><div>To estimate the proportion and identify predictors of difficult-to-treat (D2T) psoriatic arthritis (PsA).</div></div><div><h3>Methods</h3><div>A multicentre observational retrospective study was conducted with patients registered in the Rheumatic Diseases Portuguese Registry (Reuma.pt). Two different definitions were used to classify D2T PsA. The first criterion (treatment failure) is defined by the failure of<!--> <!-->≥<!--> <!-->2 b/tsDMARDs (first definition) or<!--> <!-->≥<!--> <!-->3 b/tsDMARDs (second definition), both with different MoAs; and the second criterion is defined by the presence of signs suggestive of active/progressive disease.</div></div><div><h3>Results</h3><div>In total, 1873 patients were included, of whom 3.7% (<em>n</em> <!-->=<!--> <!-->70) were classified as having D2T PsA according to the first definition and 0.9% (<em>n</em> <!-->=<!--> <!-->17) as having D2T PsA according to the second definition. D2T PsA was associated with a younger age at symptom onset (37.5<!--> <!-->±<!--> <!-->11.0 vs. 41.4<!--> <!-->±<!--> <!-->12.8; <em>P</em> <!-->&lt;<!--> <!-->0.01) and at diagnosis (40.7<!--> <!-->±<!--> <!-->10.5 vs. 44.7<!--> <!-->±<!--> <!-->12.3; <em>P</em> <!-->&lt;<!--> <!-->0.01), polyarticular phenotype (77.6% vs. 53.6%; <em>P</em> <!-->&lt;<!--> <!-->0.001), depression (10.9% vs. 5%; <em>P</em> <!-->&lt;<!--> <!-->0.05), and enthesitis (47.1% vs. 33.5%; <em>P</em> <!-->&lt;<!--> <!-->0.05) and lower body mass index (26.5[6.1] vs. 27.7[6.1]; <em>P</em> <!-->&lt;<!--> <!-->0.01). D2T PsA patients presented with higher tender (13.4[14.5] vs. 6[8]; <em>P</em> <!-->&lt;<!--> <!-->0.001) and swollen joint counts (9[9] vs. 4[6]; <em>P</em> <!-->&lt;<!--> <!-->0.001) and higher DAPSA (38.2[31.6] vs. 25.4[15.6]; <em>P</em> <!-->&lt;<!--> <!-->0.001) at baseline. Polyarticular disease (OR: 3.09), increased baseline swollen joint count (OR: 1.12), and treatment duration on the first b/tsDMARDs (<em>P</em> <!-->&lt;<!--> <!-->0.01) were predictors of D2T PsA.</div></div><div><h3>Conclusion</h3><div>D2T PsA proportions varied between 0.9% and 3.7%. D2T PsA patients had higher disease activity scores before the initiation of their first b/tsDMARDs and higher rates of treatment discontinuation.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105949"},"PeriodicalIF":4.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review","authors":"Alice Tison ,&nbsp;Thomas Escoda ,&nbsp;Marie Kostine ,&nbsp;Divi Cornec ,&nbsp;Laurent Chiche","doi":"10.1016/j.jbspin.2025.105938","DOIUrl":"10.1016/j.jbspin.2025.105938","url":null,"abstract":"<div><div>Immune checkpoint inhibitors (ICIs) have dramatically changed the management of cancer and their indications are expanding, leading to an increase in immune-related adverse events (irAEs). Recently, attention has focused on previously underestimated rheumatic irAEs, including inflammatory arthritis (IA), polymyalgia rheumatica-like phenotypes and Sicca syndrome, but also fasciitis, and rare but severe immune mediated myositis, with a possible association with myasthenia-like symptoms or myocarditis. Rheumatic irAEs may have a prolonged course and affect a patient's quality of life. Patients with IA or systemic autoimmune disease prior to ICI initiation are also at risk of flares. Current management of rheumatic toxicities relies on the opinion of experts, mostly based on the management of the classical rheumatic conditions they mimic. Due to the lack of high-quality data in the literature, few recommendations are available, with remaining concerns regarding the impact of immunosuppressive drugs on cancer response. The aim of this article is to provide practical guidelines to help rheumatologists and oncologists in their daily practice to deal with ICI related inflammatory rheumatic conditions, from the introduction of an ICI in the case of preexisting autoimmune disease, to the occurrence of rheumatic toxicity, as well as discussions concerning ICI rechallenge after a severe rheumatic irAE.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105938"},"PeriodicalIF":3.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual disease in axial spondyloarthritis. Facts and issues","authors":"Daniel Wendling ,&nbsp;Philippe Goupille ,&nbsp;Frank Verhoeven ,&nbsp;Clément Prati","doi":"10.1016/j.jbspin.2025.105943","DOIUrl":"10.1016/j.jbspin.2025.105943","url":null,"abstract":"<div><div>Residual disease in axial spondyloarthritis (axSpA) is defined by the persistence of signs, symptoms, or disease burden despite active treatment. Magnetic resonance imaging (MRI) inflammation may still be present in up to one-third of patients in clinical remission. Moreover, residual symptoms are frequently reported in patients with low disease activity (LDA), with 20–40% of patients experiencing pain or fatigue scores greater than 4 out of 10 on a visual analogue scale. Nociplastic pain (central sensitization) and neuropathic pain components are commonly associated with residual symptoms, as is female gender. Other contributing factors may include psycho-behavioral disorders, low physical activity, sarcopenia, sleep disturbances, and comorbidities. This residual disease is a key feature of difficult-to-manage (D2M) axSpA. A comprehensive assessment of the patient's context and a thorough evaluation of pain mechanisms are essential first steps in the management of these patients. Non-pharmacological strategies should be prioritized and reinforced in this setting, while certain targeted disease-modifying anti-rheumatic drugs (DMARDs) may have a specific effect on pain independently of their anti-inflammatory properties. There is a pressing need for new biomarkers that more specifically reflect the inflammatory process in spondyloarthritis, as therapeutic response is currently assessed primarily through patient-reported outcomes (PROs). Although no consensus definition exists to date, the recognition of residual disease and its associated factors is crucial in axSpA – particularly in a condition where objective signs of inflammation may be absent – to prevent overtreatment.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105943"},"PeriodicalIF":4.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}